Factors influencing the clinical outcomes of intense pulsed light for meibomian gland dysfunction

To observe the clinical outcomes of intense pulsed light (IPL) for meibomian gland dysfunction (MGD) and identify its influencing factors.Forty-eight eyes of 48 patients with MGD were included. Subjects were followed up 5 times on day 1, day 15, day 30, day 45, and day 120, and underwent 3 sessions...

Full description

Saved in:
Bibliographic Details
Published inMedicine (Baltimore) Vol. 100; no. 49; p. e28166
Main Authors Chen, Chen, Chen, Di, Chou, Yu-yu, Long, Qin
Format Journal Article
LanguageEnglish
Published United States Lippincott Williams & Wilkins 10.12.2021
Subjects
Online AccessGet full text
ISSN0025-7974
1536-5964
1536-5964
DOI10.1097/MD.0000000000028166

Cover

Loading…
Abstract To observe the clinical outcomes of intense pulsed light (IPL) for meibomian gland dysfunction (MGD) and identify its influencing factors.Forty-eight eyes of 48 patients with MGD were included. Subjects were followed up 5 times on day 1, day 15, day 30, day 45, and day 120, and underwent 3 sessions of the IPL treatment on day 1, day 15 and day 30. Gender, age, duration of MGD, time of video display terminal usage, and severity of MGD were recorded at baseline. At every visit, Ocular Surface Disease Index (OSDI), eyelid margin abnormality score, tear film breakup time, Schirmer I test (S ɪ t) and corneal fluorescein staining were recorded. The clinical parameters before and after 3 IPL treatments were compared. Univariate and multivariable logistic regression analyses were performed to explore influencing factors.Compared with baseline, the tear film breakup time was increased and the corneal fluorescein staining score and OSDI were significantly decreased on day 45 and day 120 (all P < .001). In univariate analysis, among the patients with a younger age (18-39 years), moderate MGD, higher baseline S ɪ t and higher baseline OSDI, the IPL treatment had a higher effective rate (P = .032, .004, .024, and .014 respectively). The MGD severity was strongly associated with effective IPL, and patients with moderate MGD had an OR of 22.454 compared with the severe MGD patients (OR = 22.454, 95% CI: 2.890-174.436, P = .003).IPL effectively improves clinical symptoms and some signs in MGD patients. Age, MGD severity, baseline S ɪ t and baseline OSDI are potential factors that may influence the clinical outcomes of IPL. MGD severity is an independent influencing factor.
AbstractList To observe the clinical outcomes of intense pulsed light (IPL) for meibomian gland dysfunction (MGD) and identify its influencing factors. Forty-eight eyes of 48 patients with MGD were included. Subjects were followed up 5 times on day 1, day 15, day 30, day 45, and day 120, and underwent 3 sessions of the IPL treatment on day 1, day 15 and day 30. Gender, age, duration of MGD, time of video display terminal usage, and severity of MGD were recorded at baseline. At every visit, Ocular Surface Disease Index (OSDI), eyelid margin abnormality score, tear film breakup time, Schirmer I test (S ɪ t) and corneal fluorescein staining were recorded. The clinical parameters before and after 3 IPL treatments were compared. Univariate and multivariable logistic regression analyses were performed to explore influencing factors. Compared with baseline, the tear film breakup time was increased and the corneal fluorescein staining score and OSDI were significantly decreased on day 45 and day 120 (all P  < .001). In univariate analysis, among the patients with a younger age (18–39 years), moderate MGD, higher baseline S ɪ t and higher baseline OSDI, the IPL treatment had a higher effective rate ( P  = .032, .004, .024, and .014 respectively). The MGD severity was strongly associated with effective IPL, and patients with moderate MGD had an OR of 22.454 compared with the severe MGD patients (OR = 22.454, 95% CI: 2.890-174.436, P  = .003). IPL effectively improves clinical symptoms and some signs in MGD patients. Age, MGD severity, baseline S ɪ t and baseline OSDI are potential factors that may influence the clinical outcomes of IPL. MGD severity is an independent influencing factor.
To observe the clinical outcomes of intense pulsed light (IPL) for meibomian gland dysfunction (MGD) and identify its influencing factors.Forty-eight eyes of 48 patients with MGD were included. Subjects were followed up 5 times on day 1, day 15, day 30, day 45, and day 120, and underwent 3 sessions of the IPL treatment on day 1, day 15 and day 30. Gender, age, duration of MGD, time of video display terminal usage, and severity of MGD were recorded at baseline. At every visit, Ocular Surface Disease Index (OSDI), eyelid margin abnormality score, tear film breakup time, Schirmer I test (S ɪ t) and corneal fluorescein staining were recorded. The clinical parameters before and after 3 IPL treatments were compared. Univariate and multivariable logistic regression analyses were performed to explore influencing factors.Compared with baseline, the tear film breakup time was increased and the corneal fluorescein staining score and OSDI were significantly decreased on day 45 and day 120 (all P < .001). In univariate analysis, among the patients with a younger age (18-39 years), moderate MGD, higher baseline S ɪ t and higher baseline OSDI, the IPL treatment had a higher effective rate (P = .032, .004, .024, and .014 respectively). The MGD severity was strongly associated with effective IPL, and patients with moderate MGD had an OR of 22.454 compared with the severe MGD patients (OR = 22.454, 95% CI: 2.890-174.436, P = .003).IPL effectively improves clinical symptoms and some signs in MGD patients. Age, MGD severity, baseline S ɪ t and baseline OSDI are potential factors that may influence the clinical outcomes of IPL. MGD severity is an independent influencing factor.
To observe the clinical outcomes of intense pulsed light (IPL) for meibomian gland dysfunction (MGD) and identify its influencing factors.Forty-eight eyes of 48 patients with MGD were included. Subjects were followed up 5 times on day 1, day 15, day 30, day 45, and day 120, and underwent 3 sessions of the IPL treatment on day 1, day 15 and day 30. Gender, age, duration of MGD, time of video display terminal usage, and severity of MGD were recorded at baseline. At every visit, Ocular Surface Disease Index (OSDI), eyelid margin abnormality score, tear film breakup time, Schirmer I test (S ɪ t) and corneal fluorescein staining were recorded. The clinical parameters before and after 3 IPL treatments were compared. Univariate and multivariable logistic regression analyses were performed to explore influencing factors.Compared with baseline, the tear film breakup time was increased and the corneal fluorescein staining score and OSDI were significantly decreased on day 45 and day 120 (all P < .001). In univariate analysis, among the patients with a younger age (18-39 years), moderate MGD, higher baseline S ɪ t and higher baseline OSDI, the IPL treatment had a higher effective rate (P = .032, .004, .024, and .014 respectively). The MGD severity was strongly associated with effective IPL, and patients with moderate MGD had an OR of 22.454 compared with the severe MGD patients (OR = 22.454, 95% CI: 2.890-174.436, P = .003).IPL effectively improves clinical symptoms and some signs in MGD patients. Age, MGD severity, baseline S ɪ t and baseline OSDI are potential factors that may influence the clinical outcomes of IPL. MGD severity is an independent influencing factor.ABSTRACTTo observe the clinical outcomes of intense pulsed light (IPL) for meibomian gland dysfunction (MGD) and identify its influencing factors.Forty-eight eyes of 48 patients with MGD were included. Subjects were followed up 5 times on day 1, day 15, day 30, day 45, and day 120, and underwent 3 sessions of the IPL treatment on day 1, day 15 and day 30. Gender, age, duration of MGD, time of video display terminal usage, and severity of MGD were recorded at baseline. At every visit, Ocular Surface Disease Index (OSDI), eyelid margin abnormality score, tear film breakup time, Schirmer I test (S ɪ t) and corneal fluorescein staining were recorded. The clinical parameters before and after 3 IPL treatments were compared. Univariate and multivariable logistic regression analyses were performed to explore influencing factors.Compared with baseline, the tear film breakup time was increased and the corneal fluorescein staining score and OSDI were significantly decreased on day 45 and day 120 (all P < .001). In univariate analysis, among the patients with a younger age (18-39 years), moderate MGD, higher baseline S ɪ t and higher baseline OSDI, the IPL treatment had a higher effective rate (P = .032, .004, .024, and .014 respectively). The MGD severity was strongly associated with effective IPL, and patients with moderate MGD had an OR of 22.454 compared with the severe MGD patients (OR = 22.454, 95% CI: 2.890-174.436, P = .003).IPL effectively improves clinical symptoms and some signs in MGD patients. Age, MGD severity, baseline S ɪ t and baseline OSDI are potential factors that may influence the clinical outcomes of IPL. MGD severity is an independent influencing factor.
Author Chou, Yu-yu
Long, Qin
Chen, Chen
Chen, Di
AuthorAffiliation a Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
b Key Laboratory of Ocular Fundus Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
AuthorAffiliation_xml – name: a Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
– name: b Key Laboratory of Ocular Fundus Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Author_xml – sequence: 1
  givenname: Chen
  surname: Chen
  fullname: Chen, Chen
  organization: Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
– sequence: 2
  givenname: Di
  surname: Chen
  fullname: Chen, Di
  organization: Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
– sequence: 3
  givenname: Yu-yu
  surname: Chou
  fullname: Chou, Yu-yu
  organization: Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
– sequence: 4
  givenname: Qin
  surname: Long
  fullname: Long, Qin
  organization: Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34889288$$D View this record in MEDLINE/PubMed
BookMark eNp9kU9vFSEUxYmpsa9PP4GJYelmKjDAwMbEtFZN2rjRNeExl_dQBp4D06bfXupr_dOFsCC5_M45ufeeoKOUEyD0kpJTSvTw5ur8lPw5TFEpn6AVFb3shJb8CK1aVXSDHvgxOinlGyG0Hxh_ho57rpRmSq2QvbCu5rngkHxcILmQtrjuALsYUnA24rxUlycoOPsGVUgF8H6JBUYcw3ZXsc8zniBs8hRswtto04jH2-KX5GrI6Tl66m3DX9y_a_T14v2Xs4_d5ecPn87eXXaOC6I7paXkXEtQ1veDFV5xSwUjG6KVI3YcnaJWMMHB98CAcqno4NXAhdVec9Gv0duD737ZTDA6SHW20eznMNn51mQbzL8_KezMNl8bJWWv2l2j1_cGc_6xQKlmCsVBbA1BXophkijBaYtq6Ku_s36HPMy1AfoAuDmXMoM3LlR7N44WHaKhxNzt0Fydm8c7bNr-kfbB_v8qflDd5FhhLt_jcgOz2YGNdfcLF4NmHSOMUkYJ6VpF6v4ngJ2vAA
CitedBy_id crossref_primary_10_1097_ICO_0000000000003837
crossref_primary_10_3390_jcm11164724
crossref_primary_10_1111_aos_15759
crossref_primary_10_1136_bmjopen_2023_078727
crossref_primary_10_1080_02713683_2022_2147955
crossref_primary_10_1097_ICU_0000000000001055
crossref_primary_10_21518_ms2023_485
crossref_primary_10_3390_jcm13216341
crossref_primary_10_1186_s12886_023_02939_9
Cites_doi 10.1167/iovs.14-15764
10.1167/iovs.13-11914
10.1080/02713683.2017.1406525
10.1016/j.survophthal.2019.08.007
10.1016/j.ajo.2019.02.024
10.1097/MD.0000000000016547
10.1186/s12886-019-1219-6
10.1097/ICL.0000000000000236
10.1097/ICL.0000000000000704
10.1167/iovs.17-23651
10.1016/j.jtos.2017.05.001
10.1016/j.jtos.2020.01.003
10.1007/s10792-017-0633-0
10.1167/iovs.10-6997g
10.1089/pho.2017.4402
10.1167/iovs.10-6997a
10.1177/1120672118817687
10.1111/cxo.13035
10.1167/iovs.10-6997c
10.1167/iovs.10-6997e
10.1111/cxo.12541
10.1089/pho.2014.3819
10.4103/ijo.IJO_698_17
10.1371/journal.pone.0105575
10.1016/j.jtos.2018.11.004
10.1167/iovs.10-6997f
10.1097/ICO.0000000000000735
10.3390/diagnostics9040147
10.2147/OPTO.S217639
10.1155/2016/1910694
10.1186/s12886-020-01357-5
10.1097/ICO.0000000000002217
10.1097/ICO.0000000000000563
10.1111/aos.14651
10.1016/j.clae.2017.05.003
10.1097/ICL.0000000000000294
ContentType Journal Article
Copyright Lippincott Williams & Wilkins
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. 2021
Copyright_xml – notice: Lippincott Williams & Wilkins
– notice: Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
– notice: Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. 2021
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.1097/MD.0000000000028166
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1536-5964
EndPage e28166
ExternalDocumentID PMC8663838
34889288
10_1097_MD_0000000000028166
00005792-202112100-00069
Genre Journal Article
GrantInformation_xml – fundername: the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences
  grantid: 2018PT32029
– fundername: the National Natural Science Foundation of China
  grantid: 81870685
– fundername: the Beijing Natural Science Foundation
  grantid: 7172173
GroupedDBID ---
.-D
.XZ
.Z2
01R
0R~
354
40H
4Q1
4Q2
4Q3
5GY
5RE
5VS
71W
77Y
7O~
AAAAV
AAGIX
AAHPQ
AAIQE
AAMOA
AAQKA
AARTV
AASCR
AAWTL
AAXQO
AAYEP
ABASU
ABBUW
ABCQX
ABDIG
ABFRF
ABOCM
ABVCZ
ABXVJ
ABZAD
ABZZY
ACDDN
ACEWG
ACGFO
ACGFS
ACILI
ACLDA
ACWDW
ACWRI
ACXJB
ACXNZ
ACZKN
ADGGA
ADHPY
ADNKB
ADPDF
AE6
AEFWE
AENEX
AFBFQ
AFDTB
AGOPY
AHOMT
AHQNM
AHVBC
AIJEX
AINUH
AJCLO
AJIOK
AJNWD
AJNYG
AJZMW
AKCTQ
AKULP
ALKUP
ALMA_UNASSIGNED_HOLDINGS
ALMTX
AMJPA
AMKUR
AMNEI
AOHHW
AOQMC
BQLVK
CS3
DIWNM
DU5
E.X
EBS
EEVPB
ERAAH
EX3
F2K
F2L
F2M
F2N
F5P
FCALG
FD6
FIJ
FL-
GNXGY
GQDEL
GROUPED_DOAJ
H0~
HLJTE
HYE
HZ~
H~9
IKREB
IKYAY
IN~
IPNFZ
JK3
JK8
K8S
KD2
KMI
KQ8
L-C
N9A
N~7
N~B
O9-
OAG
OAH
OB2
OHH
OK1
OL1
OLB
OLG
OLH
OLU
OLV
OLY
OLZ
OPUJH
OUVQU
OVD
OVDNE
OVEED
OVIDH
OVLEI
OWV
OWW
OWZ
OXXIT
P2P
RIG
RLZ
RPM
RXW
S4R
S4S
TAF
TEORI
TSPGW
UNMZH
V2I
VVN
W3M
WOQ
WOW
X3V
X3W
XYM
YFH
YOC
ZFV
ZY1
AAYXX
ADSXY
CITATION
8L-
ACIJW
AWKKM
CGR
CUY
CVF
ECM
EIF
NPM
ODA
7X8
5PM
ID FETCH-LOGICAL-c4509-89664496e8af37a5f84a1520b098c0addc81a5254ef3e2e146817f8745a9f9453
ISSN 0025-7974
1536-5964
IngestDate Thu Aug 21 18:45:17 EDT 2025
Tue Aug 05 10:00:08 EDT 2025
Wed Feb 19 02:24:45 EST 2025
Tue Aug 05 11:57:20 EDT 2025
Thu Apr 24 23:10:01 EDT 2025
Fri May 16 03:50:36 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 49
Language English
License Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c4509-89664496e8af37a5f84a1520b098c0addc81a5254ef3e2e146817f8745a9f9453
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-8532-0999
OpenAccessLink http://dx.doi.org/10.1097/MD.0000000000028166
PMID 34889288
PQID 2608541453
PQPubID 23479
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_8663838
proquest_miscellaneous_2608541453
pubmed_primary_34889288
crossref_citationtrail_10_1097_MD_0000000000028166
crossref_primary_10_1097_MD_0000000000028166
wolterskluwer_health_00005792-202112100-00069
PublicationCentury 2000
PublicationDate 20211210
2021-12-10
2021-Dec-10
PublicationDateYYYYMMDD 2021-12-10
PublicationDate_xml – month: 12
  year: 2021
  text: 20211210
  day: 10
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Hagerstown, MD
PublicationTitle Medicine (Baltimore)
PublicationTitleAlternate Medicine (Baltimore)
PublicationYear 2021
Publisher Lippincott Williams & Wilkins
Publisher_xml – name: Lippincott Williams & Wilkins
References Arita (R5-20250504) 2020; 103
Pinto-Fraga (R20-20250504) 2017; 43
Geerling (R38-20250504) 2011; 52
Craig (R7-20250504) 2015; 56
Albietz (R36-20250504) 2018; 101
Fu (R15-20250504) 2019; 98
Schaumberg (R1-20250504) 2011; 52
Yin (R34-20250504) 2018; 43
Yamaguchi (R32-20250504) 2018; 59
Arita (R22-20250504) 2019; 17
Chan (R3-20250504) 2019; 25
Rong (R8-20250504) 2018; 36
Tang (R25-20250504) 2020; 47
Giannaccare (R31-20250504) 2019; 11
Vegunta (R10-20250504) 2016; 35
Xue (R30-20250504) 2020; 18
Karaca (R24-20250504) 2020; 30
Huang (R19-20250504) 2019; 19
Titiyal (R23-20250504) 2018; 66
Wolffsohn (R16-20250504) 2017; 15
Wu (R12-20250504) 2014; 9
Villani (R27-20250504) 2013; 54
Nichols (R17-20250504) 2011; 52
Toyos (R35-20250504) 2015; 33
Hashemi (R37-20250504) 2017; 40
Sabeti (R4-20250504) 2020; 65
Jiang (R13-20250504) 2016; 2016
Knop (R26-20250504) 2011; 52
Vigo (R33-20250504) 2019; 9
Na (R21-20250504) 2021; 99
Kuriakose (R28-20250504) 2018; 38
Chatterjee (R2-20250504) 2020; 39
Liang (R29-20250504) 2015; 34
Tomlinson (R6-20250504) 2011; 52
Paugh (R14-20250504) 2018; 44
Ge (R18-20250504) 2020; 20
Arita (R11-20250504) 2019; 207
References_xml – volume: 56
  start-page: 1965
  year: 2015
  ident: R7-20250504
  article-title: Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction
  publication-title: Invest Ophthalmol Vis Sci
  doi: 10.1167/iovs.14-15764
– volume: 54
  start-page: 4735
  year: 2013
  ident: R27-20250504
  article-title: The aging Meibomian gland: an in vivo confocal study
  publication-title: Invest Ophthalmol Vis Sci
  doi: 10.1167/iovs.13-11914
– volume: 43
  start-page: 308
  year: 2018
  ident: R34-20250504
  article-title: Changes in the meibomian gland after exposure to intense pulsed light in meibomian gland dysfunction (MGD) patients
  publication-title: Curr Eye Res
  doi: 10.1080/02713683.2017.1406525
– volume: 65
  start-page: 205
  year: 2020
  ident: R4-20250504
  article-title: Management of meibomian gland dysfunction: a review
  publication-title: Surv Ophthalmol
  doi: 10.1016/j.survophthal.2019.08.007
– volume: 207
  start-page: 410
  year: 2019
  ident: R11-20250504
  article-title: Meibomian gland dysfunction and dry eye are similar but different based on a population-based study: the hirado-takushima study in Japan
  publication-title: Am J Ophthalmol
  doi: 10.1016/j.ajo.2019.02.024
– volume: 98
  start-page: e16547
  year: 2019
  ident: R15-20250504
  article-title: Evaluation of ocular surface impairment in meibomian gland dysfunction of varying severity using a comprehensive grading scale
  publication-title: Medicine (Baltimore)
  doi: 10.1097/MD.0000000000016547
– volume: 19
  start-page: 211
  year: 2019
  ident: R19-20250504
  article-title: Clinical results of intraductal meibomian gland probing combined with intense pulsed light in treating patients with refractory obstructive meibomian gland dysfunction: a randomized controlled trial
  publication-title: BMC Ophthalmol
  doi: 10.1186/s12886-019-1219-6
– volume: 43
  start-page: 57
  year: 2017
  ident: R20-20250504
  article-title: Efficacy and safety of 0.2% hyaluronic acid in the management of dry eye disease
  publication-title: Eye Contact Lens
  doi: 10.1097/ICL.0000000000000236
– volume: 47
  start-page: 38
  year: 2020
  ident: R25-20250504
  article-title: A retrospective study of treatment outcomes and prognostic factors of intense pulsed light therapy combined with meibomian gland expression in patients with meibomian gland dysfunction
  publication-title: Eye Contact Lens
  doi: 10.1097/ICL.0000000000000704
– volume: 59
  start-page: DES192
  year: 2018
  ident: R32-20250504
  article-title: Inflammatory response in dry eye
  publication-title: Invest Ophthalmol Vis Sci
  doi: 10.1167/iovs.17-23651
– volume: 25
  start-page: 38
  year: 2019
  ident: R3-20250504
  article-title: Update on the association between dry eye disease and meibomian gland dysfunction
  publication-title: Hong Kong Med J
– volume: 15
  start-page: 539
  year: 2017
  ident: R16-20250504
  article-title: TFOS DEWS II diagnostic methodology report
  publication-title: Ocul Surf
  doi: 10.1016/j.jtos.2017.05.001
– volume: 18
  start-page: 286
  year: 2020
  ident: R30-20250504
  article-title: Randomised double-masked placebo-controlled trial of the cumulative treatment efficacy profile of intense pulsed light therapy for meibomian gland dysfunction
  publication-title: Ocul Surf
  doi: 10.1016/j.jtos.2020.01.003
– volume: 38
  start-page: 1809
  year: 2018
  ident: R28-20250504
  article-title: Dyslipidemia and its association with meibomian gland dysfunction: a systematic review
  publication-title: Int Ophthalmol
  doi: 10.1007/s10792-017-0633-0
– volume: 52
  start-page: 2050
  year: 2011
  ident: R38-20250504
  article-title: The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction
  publication-title: Invest Ophthalmol Vis Sci
  doi: 10.1167/iovs.10-6997g
– volume: 36
  start-page: 326
  year: 2018
  ident: R8-20250504
  article-title: Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction
  publication-title: Photomed Laser Surg
  doi: 10.1089/pho.2017.4402
– volume: 52
  start-page: 1922
  year: 2011
  ident: R17-20250504
  article-title: The international workshop on meibomian gland dysfunction: executive summary
  publication-title: Invest Ophthalmol Vis Sci
  doi: 10.1167/iovs.10-6997a
– volume: 30
  start-page: 289
  year: 2020
  ident: R24-20250504
  article-title: Intense regulated pulse light for the meibomian gland dysfunction
  publication-title: Eur J Ophthalmol
  doi: 10.1177/1120672118817687
– volume: 103
  start-page: 742
  year: 2020
  ident: R5-20250504
  article-title: Non-pharmaceutical treatment options for meibomian gland dysfunction
  publication-title: Clin Exp Optom
  doi: 10.1111/cxo.13035
– volume: 52
  start-page: 1938
  year: 2011
  ident: R26-20250504
  article-title: The international workshop on meibomian gland dysfunction: report of the subcommittee on anatomy, physiology, and pathophysiology of the meibomian gland
  publication-title: Invest Ophthalmol Vis Sci
  doi: 10.1167/iovs.10-6997c
– volume: 52
  start-page: 1994
  year: 2011
  ident: R1-20250504
  article-title: The international workshop on meibomian gland dysfunction: report of the subcommittee on the epidemiology of, and associated risk factors for, MGD
  publication-title: Invest Ophthalmol Vis Sci
  doi: 10.1167/iovs.10-6997e
– volume: 101
  start-page: 23
  year: 2018
  ident: R36-20250504
  article-title: Intense pulsed light treatment and meibomian gland expression for moderate to advanced meibomian gland dysfunction
  publication-title: Clin Exp Optom
  doi: 10.1111/cxo.12541
– volume: 33
  start-page: 41
  year: 2015
  ident: R35-20250504
  article-title: Intense pulsed light treatment for dry eye disease due to meibomian gland dysfunction; a 3-year retrospective study
  publication-title: Photomed Laser Surg
  doi: 10.1089/pho.2014.3819
– volume: 66
  start-page: 207
  year: 2018
  ident: R23-20250504
  article-title: Prevalence and risk factors of dry eye disease in North India: ocular surface disease index-based cross-sectional hospital study
  publication-title: Indian J Ophthalmol
  doi: 10.4103/ijo.IJO_698_17
– volume: 9
  start-page: e105575
  year: 2014
  ident: R12-20250504
  article-title: Meibomian gland dysfunction determines the severity of the dry eye conditions in visual display terminal workers
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0105575
– volume: 17
  start-page: 104
  year: 2019
  ident: R22-20250504
  article-title: Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction
  publication-title: Ocul Surf
  doi: 10.1016/j.jtos.2018.11.004
– volume: 52
  start-page: 2006
  year: 2011
  ident: R6-20250504
  article-title: The international workshop on meibomian gland dysfunction: report of the diagnosis subcommittee
  publication-title: Invest Ophthalmol Vis Sci
  doi: 10.1167/iovs.10-6997f
– volume: 35
  start-page: 318
  year: 2016
  ident: R10-20250504
  article-title: Combination therapy of intense pulsed light therapy and meibomian gland expression (IPL/MGX) can improve dry eye symptoms and meibomian gland function in patients with refractory dry eye: a retrospective analysis
  publication-title: Cornea
  doi: 10.1097/ICO.0000000000000735
– volume: 9
  start-page: 147
  year: 2019
  ident: R33-20250504
  article-title: Ocular surface workup in patients with meibomian gland dysfunction treated with intense regulated pulsed light
  publication-title: Diagnostics (Basel)
  doi: 10.3390/diagnostics9040147
– volume: 11
  start-page: 113
  year: 2019
  ident: R31-20250504
  article-title: Intense pulsed light therapy in the treatment of meibomian gland dysfunction: current perspectives
  publication-title: Clin Optom (Auckl)
  doi: 10.2147/OPTO.S217639
– volume: 2016
  start-page: 1910694
  year: 2016
  ident: R13-20250504
  article-title: Evaluation of the safety and effectiveness of intense pulsed light in the treatment of meibomian gland dysfunction
  publication-title: J Ophthalmol
  doi: 10.1155/2016/1910694
– volume: 20
  start-page: 111
  year: 2020
  ident: R18-20250504
  article-title: Evaluation of the efficacy of optimal pulsed technology treatment in patients with cataract and Meibomian gland dysfunction in the perioperative period
  publication-title: BMC Ophthalmol
  doi: 10.1186/s12886-020-01357-5
– volume: 39
  start-page: 634
  year: 2020
  ident: R2-20250504
  article-title: Meibomian gland dysfunction in a hospital-based population in Central India
  publication-title: Cornea
  doi: 10.1097/ICO.0000000000002217
– volume: 34
  start-page: 1193
  year: 2015
  ident: R29-20250504
  article-title: Evaluation of optical coherence tomography meibography in patients with obstructive meibomian gland dysfunction
  publication-title: Cornea
  doi: 10.1097/ICO.0000000000000563
– volume: 99
  start-page: 489
  year: 2021
  ident: R21-20250504
  article-title: Therapeutic effects of acupuncture in typical dry eye: a systematic review and meta-analysis
  publication-title: Acta Ophthalmol
  doi: 10.1111/aos.14651
– volume: 40
  start-page: 213
  year: 2017
  ident: R37-20250504
  article-title: Meibomian gland dysfunction and its determinants in Iranian adults: a population-based study
  publication-title: Cont Lens Anterior Eye
  doi: 10.1016/j.clae.2017.05.003
– volume: 44
  start-page: 06
  year: 2018
  ident: R14-20250504
  article-title: Development of a meibomian gland dysfunction-specific symptom questionnaire
  publication-title: Eye Contact Lens
  doi: 10.1097/ICL.0000000000000294
SSID ssj0013724
Score 2.4160862
Snippet To observe the clinical outcomes of intense pulsed light (IPL) for meibomian gland dysfunction (MGD) and identify its influencing factors.Forty-eight eyes of...
To observe the clinical outcomes of intense pulsed light (IPL) for meibomian gland dysfunction (MGD) and identify its influencing factors. Forty-eight eyes of...
SourceID pubmedcentral
proquest
pubmed
crossref
wolterskluwer
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage e28166
SubjectTerms Adolescent
Adult
Dry Eye Syndromes - therapy
Female
Fluoresceins
Humans
Intense Pulsed Light Therapy
Male
Meibomian Gland Dysfunction - therapy
Meibomian Glands
Observational Study
Young Adult
Title Factors influencing the clinical outcomes of intense pulsed light for meibomian gland dysfunction
URI https://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00005792-202112100-00069
https://www.ncbi.nlm.nih.gov/pubmed/34889288
https://www.proquest.com/docview/2608541453
https://pubmed.ncbi.nlm.nih.gov/PMC8663838
Volume 100
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBZZCmMwxu7LLkWDvWXqbFmypcetSSlj3Ri0o29GtmUalsaliSndr9-RdcmloazLgxMUWZFzPknnSOd8B6EPiqoqTktOUhlzwoqKElkWKalTlkVVEhu-FONt8T09PGFfT_lpr7fqtdQuir3yz9a4kv-RKpSBXE2U7B0kGxqFAvgM8oUrSBiu_yTjA5csZ-IyjfjQpxDu2LQL-F3HK9s5q-vhRQurYTWcGqu8czI815OiOTcDvcvnMayu52a1CxLz-Z7cKbzRSb-o6WJiXXTDRsK-i_Mw75tlo8mypGm7ab8l160v_Ob8gn86GnC3C0Fj49Hh_FF9VIChvrQZd_a0n0xTwqVlKQ-zbRStwMrSlbrJU1NziLl1Xrd8wUcjSzdpX6H2Oov2xuoWfA79afvRKN9s5B7aoWBl0D7a-fFrPB4tj6EyykLOX3g4T1sls09b-rKu2tywV2663T68aoxLxPx3FxGxotccP0aPnEGCP1t0PUE9PXuK7nthP0PKgQyvgAwDyLAHGfYgw02NHciwBRnuQIYBZDiADHcgwysge45ODsbH-4fE5eUgJQP9kggwkRmTqRaqTjLFa8EUqIFREUlRRrBgliJWnHKm60RTbYL74qw2eRWUrCXjyQvUnzUz_QphXaoqqVlcFgwsfZEoXZeglIOZDK2CdjVA1P-leelI603ulGl-izgH6GO46cJyttxe_b2XVQ5zqzkwUzPdtPMcbH3BoWMc-vHSyi40mMDKJ6kQA5StSTVUMLzt69_MJmcdf7sALV8kcCdZk39uI5-7_vFMUmLGmeH366gfUvn6bo_1Bj1YDtS3qL-4bPU7UKAXxW638bTrwP4X_sC9dQ
linkProvider Ovid
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lj9MwELagKwESQrwpTyOhnAgkjp3Yhx6qNqUs24LULrucIiexRcVuUpEWxL9nJo9CWYFELokU24oyE8_3ZV6EvNBM536YCTdUvnB5mjNXZWno2pBHXh74WC8Foy3m4fSYH56K0zbaAnNhMPusWr_CU71P4wX2w0FiuBwcLpx5fLIYFM5oMRp8cj4M38T1f2qMknDGg_Kb3TjDeR1_JSLFQAeA4ACrqbOnQ3WZHISCRV6PHLz_GMfjX_6GiPFdc1eA2F19IhW9no2bGofNwdDPtm_DLgDTi_GV17-X6PuuvtSh778ZsMlNcqNFnnTYqMotcskUt8mVWetbv0P0pGm9Q1dt3xIwahTgIe2SJ2m53cDLMhUtLV3Voe-GrrdgW3N6hhyfAgCm52aVluegdLTuDkLzHxXaTpT_XXI8iZejqds2YHAzDkDClcCFOFehkdoGkRZWcg323ks9JTMPdsZM-loAxTQ2MMxgFpcfWSygr5VVXAT3SK8oC_OAUJPpPLDcz1IOlE4G2tgM0BfwIVgVzGifsO6VJllbnRybZJwlnZd8Nk7-lEOfvNxNWjfFOf49_HknqwQ-IvSM6MKU2yoBUiexH7qA57jfyG63YABbnGJS9km0J9XdACzQvX-nWH2uC3VLgHMygJnunvyTJsU1-ZuWPvzP8c_I1elydpQcvZ2_e0Su4V0MuPG9x6S3-bo1TwA2bdKnrc7_BNkvCzs
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELdGJ01ICI3vwgZGQnkiKB9OYj_kYWpSxqDdpG6wPUWOY4uKLalIC9p_z10-OsoQEnlppDhWlHN8v1_v7neEvJGeLNxQBXYo3MBmeeHZQuWhbUIWOYXvol4KZltMw8MzdnQenG-RPmKKxWf14h3-NNs0nmA7HOSFp_HRzBrNRvGFNU2_zOKpdXLwPm3-psYkCeskGcfXVhJXP8zSSo7jXp9xkrQihe3hYaDsDtnmPHTYgGwff07T5CbuEHls3eQVoHavU_T3aTZ92S2AejvP8t7PCmPg9bcmBf43RzbeJfc7BEoP2iXzgGzp8iHZmXQx9kdEjtsWPHTe9S8B50YBJtK-iJJWqyW8NV3TytB5kwKv6WIFPragl8j1KQBheqXneXUFi482XUJocV2jD8V18JicjdPT0aHdNWKwFQNAYXPgRIyJUHNp_EgGhjMJft_JHcGVAzuk4q4MgGpq42tPYzWXGxkU0pfCCBb4T8igrEr9jFCtZOEb5qqcAbXjvtRGAQoDXgSzgjsdEq9_pZnqVMqxWcZl1kfLJ0n2px2G5O36pkUr0vHv4a97W2XwMWGERJa6WtUZkDuOfdEDeI6nre3WE_qw1QmP8yGJNqy6HoBC3ZtXyvnXRrCbA6zjPtxpb9g_a0tdm-cLIuHBjgV0HDh4U-sfiuf_Of4V2YFvIPv0YfrxBbmLFzHvxnX2yGD5faX3AT0t85fdkv8FAasM0A
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Factors+influencing+the+clinical+outcomes+of+intense+pulsed+light+for+meibomian+gland+dysfunction&rft.jtitle=Medicine+%28Baltimore%29&rft.au=Chen%2C+Chen&rft.au=Chen%2C+Di&rft.au=Chou%2C+Yu-yu&rft.au=Long%2C+Qin&rft.date=2021-12-10&rft.issn=0025-7974&rft.eissn=1536-5964&rft.volume=100&rft.issue=49&rft.spage=e28166&rft_id=info:doi/10.1097%2FMD.0000000000028166&rft.externalDBID=n%2Fa&rft.externalDocID=10_1097_MD_0000000000028166
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0025-7974&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0025-7974&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0025-7974&client=summon